The FDA is giving RP1 a “third” chance. Replimune (REPL) announced that it has aligned with the FDA on a path forward for resubmitting its application for RP1, and the agency has agreed to treat the review as an urgent matter. Shares spiked over 90% on Friday.
The news comes directly on the heels of FDA Commissioner Marty Makary’s departure earlier this month. Makary was the commissioner whose agency had rejected the drug twice.